Drugs / 68Ga-NOTA-PEG2-RM26
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06147362 | Jun 2022 → Dec 2023 | cancer | Karolinska University Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NOTA-PEG2-RM26 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06147362 ↗ |
| Known as | [(68)Ga]Ga-NOTA-PEG(2)-RM26 | “First-in-human radiation dosimetry of the GRPR antagonist [(68)Ga]Ga-NOTA-PEG(2)-RM26 in patients with prostate and breast cancer.” PMID 42310173 ↗ Jun 2026 |
| Action | Inhibit | “Single-dose 68Ga-NOTA-PEG2-RM26, a gastrin-releasing peptide receptor antagonist linked with a positron emitting radioisotope intravenously injected into participants before...” NCT06147362 ↗ |
| Modality | Peptide | “RM26, a GRPR antagonist with high affinity, was discovered by peptide backbone modification of bombesin analogues.” NCT06147362 ↗ |
| Route | Intravenous | “intravenously injected” NCT06147362 ↗ |